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Abstract
Nucleosomes appear spontaneously in elevated concen-
trations in the serum of patients with malignant diseases
as well as during chemo- and radiotherapy. We analyzed
whether their kinetics show typical characteristics during
radiochemotherapy and enable an early estimation of
therapy efficacy. We used the Cell Death Detection Eli-
saplus (Roche Diagnostics) and investigated the course of
nucleosomes in the serum of 32 patients with a local stage
of pancreatic cancer who were treated with radiochemo-
therapy for several weeks. Ten of them received postsur-
gical therapy, 21 received primary therapy and 1 received
therapy for local relapse. Blood was taken before the
beginning of therapy, daily during the first week, once
weekly during the following weeks and at the end of radio-
chemotherapy. The response to therapy was defined
according to the kinetics of CA 19-9: a decrease of CA 19-9
650% after radiochemotherapy was considered as ‘re-
mission’; an increase of 6100% (which was confirmed by
two following values) was defined as ‘progression’. Pa-
tients with ‘stable disease’ ranged intermediately. Most of
the examined patients showed a decrease of the concen-
tration of nucleosomes within 6 h after the first dose of
radiation. Afterwards, nucleosome levels increased rapid-
ly, reaching their maximum during the following days.
Patients receiving postsurgery, primary or relapse thera-
pies did not show significant differences in nucleosome
values during the time of treatment. Single nucleosome
values, measured at 6, 24 and 48 h after the application of
therapy, could not discriminate significantly between pa-
tients with no progression and those with progression of
disease. However, the area under the curve of the first 3
days, which integrated all variables of the initial thera-
peutic phase, showed a significant correlation with the
progression-free interval (p = 0.008). Our results indicate
that the area under the curve of nucleosomes during the
initial phase of radiochemotherapy could be valuable for
the early prediction of the progression-free interval.
Copyright © 2005 S. Karger AG, Basel
Introduction
For cellular homeostasis in humans, a balance between
cellular proliferation and elimination is of great impor-
tance [1]. Several physiological and pathological stimuli
lead to cell death. In case of lethal cell damage, apoptotic
cell death is induced by the activation of a cascade of
enzymes. During this procedure, many cellular structures
are degraded by activated caspases. Chromatin is cleaved
by endonucleases at the DNA-linking sites into mono-
and oligonucleosomes [1–4]. These are composed of a
core particle of histones and DNA that is twisted around
it [5, 6]. During apoptosis, these particles are phagocy-
tized by neighboring cells and macrophages or are re-
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leased into circulation [1, 2]. There they can be quantified
by immunological methods [7]. Nucleosomes can be de-
tected in low amounts in the serum of healthy individuals
[8, 9] and appear in higher concentrations in the serum of
patients with various benign and malignant diseases [re-
viewed in 10], such as in patients suffering from autoim-
mune diseases [11, 12], after trauma [13], during graft
rejection [14, 15], after stroke [16], as well as in cancer
patients, spontaneously and during chemo- and radiother-
apy [9, 17, 18].
After the disintegration of the cell membrane, nucleo-
somes are released into circulation and are quickly elimi-
nated [19]. Thus, the concentration of nucleosomes in the
serum can be considered a correlative for the extent of cell
death at a certain time. In patients with malignant dis-
eases, the spontaneous rate of cell death might contain
information on the tumor activity, whereas the induced
rate of cell death during chemo- or radiotherapy might
indicate the effects of the treatment.
Nowadays, the efficacy of therapy in patients with sol-
id tumors is mostly controlled by imaging techniques like
ultrasonography, X-ray, computed tomography, magnetic
resonance tomography and positron emission tomogra-
phy. Particularly in pancreatic cancer, it often takes a long
time until the effects of radiotherapy on the tumor can be
estimated by these imaging techniques. In addition, the
local effects of the applied therapy alter the surrounding
tissue structure in the irradiation field, hampering an
objective judgment of the actual tumor size. However, it
would be very useful to know the tumor response to radio-
chemotherapy as early as possible, in order to optimize
the therapeutic protocol and to avoid unnecessary side
effects. Therefore, we investigated the courses of nucleo-
somes in the serum of patients with pancreatic cancer dur-
ing radiochemotherapy, asking whether typical kinetic
patterns of nucleosomes occur and whether they can early
predict the efficacy of therapy.
Methods and Patients
Methods
For the quantification of nucleosome concentrations in serum,
we used the Cell Death Detection Elisaplus (Roche Diagnostics). Two
monoclonal mouse antibodies, which are directed against histones
and DNA, respectively, catch the nucleosomes specifically. The anti-
histone antibody additionally binds to the microtiter plate, and the
anti-DNA antibody, which is labeled with peroxidase, reacts with the
2,2)-azino-di(3-ethylbenzthiazolin-sulfonate) substrate. The amount
of nucleosomes which are captured by the antibodies is proportional
to the resulting color development and enables the photometric
quantification in arbitrary units (AU).
We used serum samples for the determination of nucleosomes
and performed the preanalytical handling of the samples as described
in Holdenrieder et al. [7]; that is, within 1–2 h after venipuncture, the
blood samples were centrifuged at 3,000 g for 15 min. Subsequently,
the serum samples were stabilized by adding 10 mM EDTA and
stored at –80°C. Prior to the measurement of nucleosomes, samples
were thawed, homogenized and diluted 1:4 with an incubation buff-
er. The course of nucleosomes of 1 patient was determined within
one run of the enzyme immunoassay to minimize the methodical
variance.
In addition, we examined CA 19-9 by Elecsys 2010 (Roche Diag-
nostics) in all serum samples.
Patients
In total, 32 patients with pancreatic cancer were included in our
study. All patients were treated with a combination of radio- and
concurrent chemotherapy. Among them were 10 with postsurgery
therapy, 21 with primary therapy and 1 with local relapse therapy.
Radiotherapy was applied in single fractions of 1.8–2.0 Gy for
5 days a week over a period of 5 weeks up to a total dose rate of 45–
50 Gy (dose rate according to ICRU 50). In addition, gemcitabine
(300 mg/m2) and cisplatin (30 mg/m2) were applied on days 1, 8, 22
and 29 or, alternatively, gemcitabine (300 mg/m2) on days 1, 15 and
29 and 5-fluorouracil (350 mg/m2) daily. Blood was taken before the
beginning of therapy, 6 h after the first radiation, daily during the
first week, once weekly during the following weeks and at the end of
radiochemotherapy. Some patients were also followed up several
months after radiochemotherapy. The observation time of all pa-
tients was 1.7–16 months. Before the first venipuncture, all patients
having been recruited for this study gave their written informed con-
sent. The study was approved by the local ethical committee.
Regarding the response to therapy, patients were subdivided into
groups depending on the change of CA 19-9 up to 2 months after the
end of therapy. A decrease of 650% of the pretherapeutic CA 19-9
value was considered as partial remission [20, 21]. Progressive dis-
ease was defined as an increase of CA 19-9 6100% which was con-
firmed by two further results with increased values [22]. Patients
with stable disease ranged intermediately.
The progression-free interval was defined as the time without
increase 6100% of the pretherapeutic CA 19-9 value.
Statistics
For our evaluation, we combined the patients with partial remis-
sion and stable disease into ‘no progression’. They were compared
with patients who suffered from progressive disease. For the statisti-
cal analysis of the difference between the two groups, the Wilcoxon
test was used. For the analysis of the progression-free interval, we
used the Kaplan-Meier method and the log-rank test. The medians of
the whole sample were used as cut-offs. A p value !0.05 was consid-
ered statistically significant. All calculations were performed by soft-
ware of SAS (version 8.2, SAS Institute Inc., Cary, N.C., USA).
Results
Concerning the response to therapy, 8 out of the 32
patients showed a partial remission, 17 had stable disease
and 7 developed metastases, which were discovered at
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the end of therapy. Ten patients underwent surgery and
received postsurgery radiochemotherapy. Eight among
them showed stable disease and 2 developed metastases
until the end of therapy. Twenty-one patients were treated
with primary radiochemotherapy. Eight among them
reached a remission, 8 had stable disease and 5 suffered
from progressive disease. The patient with local relapse
had a stable disease.
Regarding the progression-free interval, 15 (median:
9.7 months) out of 32 patients had no progression, where-
as 17 patients (median: 6.1 months) developed systemic
metastases during the observation time.
Most of the examined patients showed a significant
decrease of the concentration of nucleosomes within 6 h
after the first radiation fraction had been applied. Nucleo-
some levels were rising again rapidly, reaching the maxi-
mum during the following days. Figures 1 and 2 show typ-
ical courses of nucleosome concentrations during radio-
chemotherapy for 1 patient suffering from progression
and 1 with a remission of disease, according to the kinet-
ics of CA 19-9.
No significant differences in nucleosome values during
the time of treatment were observed in patients receiving
postsurgery, primary and relapse therapy concerning the
pretherapeutic value or the values during the following 3
days (day 1 (6 h), day 2, day 3), as well as for the minimal
value, the maximal value, the area under the curve during
the first week (AUC1–7) and the area under the curve dur-
ing the first 3 days (AUC1–3). Therefore, the results from
all patients were combined for the evaluation of the pre-
diction of therapy efficacy by nucleosomes in the serum
(table 1).
Fig. 2. Course of nucleosomes of a patient with pancreatic cancer
during primary radiochemotherapy with remission of disease. The
increase of nucleosome concentrations during the initial phase of the
treatment is less pronounced, resulting in a smaller AUC.
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Table 1. Median and range of nucleosome values of several variables
during the first week
Postsurgery
therapy
Primary + relapse
therapy
p
value
Before therapy 581 (278–1,836) 581 (278–1,836) 0.611
Day 1 (6 h) 417 (267–842) 364 (116–1,322) 0.616
Day 2 529 (121–2,404) 601 (123–6,362) 0.627
Day 3 396 (198–1,385) 758 (193–2,883) 0.353
Minimum 247 (100–829) 220 (39–611) 0.708
Maximum 1,378 (599–3,965) 1,390 (442–6,901) 0.878
AUC1–7 4,560 (2,285–10,232) 4,655 (1,819–18,173) 0.982
AUC1–3 962 (508–3,284) 1,107 (455–6,640) 0.438
In order to prove the validity of the biochemical
response to therapy by CA 19-9 as a secondary end-point
for the success of radiochemotherapy, it was tested for its
correlation with the overall survival. Patients with bio-
chemically no progression (increase of CA 19-9 !100%)
showed a significantly longer overall survival than pa-
tients with biochemical progression of disease (increase of
CA 19-9 6100%; p = 0.025; fig. 3).
Concerning the biochemical response to therapy by CA
19-9, nucleosomes showed slightly lower values for pa-
tients with no progression compared with those with pro-
gression for the 6-hour value (median: 367 AU; no pro-
gression: 50% 1 median, progression: 67% 1 median; p =
0.590), the value at day 1 (median: 601 AU; no progres-
sion: 48% 1 median, progression: 67% 1 median; p =
0.411), the value at day 2 (median: 651 AU; no progres-
Fig. 1. Course of nucleosomes of a patient with pancreatic cancer
during primary radiochemotherapy who suffered from progression of
disease, according to CA 19-9 kinetics. Nucleosome levels show a
considerable increase during the first week of the therapy, resulting in
a large AUC.
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Fig. 3. Correlation of the biochemical response to therapy by CA
19-9 with the overall survival. Patients with biochemically no pro-
gression (increase of CA 19-9 !100%) showed a significantly longer
overall survival than patients with biochemical progression of dis-
ease (increase of CA 19-9 6 100%; p = 0.025).
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Fig. 4. Percentage of patients with no progression ()) and with pro-
gression ($) of disease after radiochemotherapy exhibiting nucleo-
some values (AU) higher than the median of all patients investigated.
The discriminating power between both groups is indicated by p val-
ues (¯2) for the nucleosome values 6, 24, 48 h after the application of
therapy and the AUC1–3 which integrated all variables of the initial
therapeutic phase.
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sion: 50% 1 median, progression: 57% 1 median; p =
0.745) and particularly for the AUC1–3 (median:
993 AU Wd; no progression: 44% 1 median, progression:
100% 1 median; p = 0.073), although this had only bor-
derline significance (fig. 4).
The AUC1–3 integrated the information of all variables
during the initial phase of the therapy and revealed a
Fig. 5. Correlation of the AUC1–3 and the progression-free interval.
Patients with AUC1–3 smaller than the median were shown to have a
significantly longer progression-free interval than those with AUC1–3
higher than the median (p = 0.008).
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potential for the early prediction of the progression-free
interval: patients with an AUC1–3 lower than the median
(993 AU Wd) corresponded with a significantly longer pro-
gression-free interval compared with those with higher
values (p = 0.008; fig. 5).
Discussion
Nowadays, there are various therapeutic options in
oncological diseases. In early stages, the primary ap-
proach is often the complete resection of the tumor. Sub-
sequent postsurgery therapies like chemo- or radiochemo-
therapy are added in many cases to eliminate remaining
tumor cells. Concerning radiotherapy, a fractionated pro-
tocol protects especially benign tissues, as they are more
capable of repairing DNA damage effectively during the
radiation-free interval than malignant cells [23]. If there is
lethal damage, cells might undergo apoptotic cell death
resulting in the release of mono- and oligonucleosomes
into circulation [1, 24, 25].
It is known that in tumor tissue, massive cell prolifera-
tion and cell death exist at the same time. This turnover of
cells, including the release of apoptotic products, varies
between different kinds of cancers and also between indi-
viduals [26]. As pancreatic cancer is often diagnosed only
in advanced stages, we expected to find high rates of
nucleosomes pretherapeutically as well as during therapy.
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The course of nucleosomes typically started at a high level
and decreased 6 h after the first application, followed by a
rapid increase reaching the maximum during the follow-
ing days.
Already the first radiation might lead to strong physi-
cal and chemical changes, such as a change of the ionic
setting, the production of free radicals and reactive prod-
ucts resulting in alterations of many cell structures and
biological cell damage. On the DNA level, changes appear
primarily in the form of single-strand breaks [27]. In order
to enable the repair of the damage, cells are commonly
arrested in the G0 phase. In the case of successful repair,
they will continue their cell cycle from the G1 phase to the
S phase. If the damage is too severe, cells will mainly
undergo apoptotic cell death after a certain time of delay
[24, 28–30]. Subsequently, various apoptotic products
like nucleosomes are released into circulation. This sce-
nario would explain the decrease of the nucleosome val-
ues 6 h after the first application followed by the steep
increase.
Besides tumor cells, normal cells – particularly those
with a high proliferation rate – might also be affected by
radiochemotherapy [31, 32] and contribute to the in-
crease of the amount of nucleosomes in circulation. We
questioned whether this was just a minor effect and com-
pared the nucleosome concentrations in patients with
postsurgery and primary radiochemotherapy. The former
received tumor resection before therapy and were sup-
posed to be free of any tumor burden, whereas the latter
still had obvious tumor masses. Because we could not find
substantial differences concerning the nucleosome levels
in both groups, we reinvestigated the pathological out-
come of the resected patients. Interestingly, in none of the
patients could the tumor be removed with the required
safety margins, which means that in all patients with post-
surgery radiochemotherapy, microscopic tumor residues
were still present.
As shown by a recent in vitro study on normal and
malignant lung cell lines that were irradiated with various
dose rates, the release of nucleosomes was significantly
higher in tumor cells than in normal bronchial cells after
irradiation with low-dose rates [33]. However, as the vol-
umes of tumor and normal tissues in the radiation field
might differ and ‘normal’ tissue might consist of various
cell types with different radiosensitivities, it is difficult to
indicate the exact contribution of normal and malignant
tissues to the release of nucleosomes in vivo.
Pancreatic cancer is known to be an aggressive disease
with limited prognosis. If a primary resection of the tumor
is not possible, radiochemotherapy nowadays is consid-
ered as standard palliative therapy aiming at the prolon-
gation of the progression-free interval [34, 35]. The re-
sponse to therapy can be controlled either by imaging
techniques or by oncological biomarkers as correlates.
Current experiences encourage the use of oncological bio-
markers such as CA 19-9 that indicate the biochemical
response in time [36, 37], whereas the evaluation by imag-
ing techniques is often not standardized, implicating con-
siderable variations due to different technique and inves-
tigator standards. However, to estimate early the response
to therapy – which would be helpful for the management
of the treatment – biochemical markers with high tumor
specificity and serum kinetics that are associated with
therapy would be useful.
Although nucleosomes in the serum are lacking tumor
specificity, they have a short half-life under physiological
conditions [38, 39] and show characteristic courses with
considerable peaks during the first week of therapy.
Therefore, we supposed that they had predictive potential
already at the initial phase of therapy.
Concerning therapy response, single nucleosome val-
ues at defined time points unfortunately could not dis-
criminate significantly between patients with no progres-
sion and those with progression of disease. The AUC1–3,
which integrated all variables of the initial therapeutic
phase, also showed only a borderline-significant correla-
tion with therapy response. However, regarding the pro-
gression-free interval, the AUC distinguished significant-
ly between patients who suffered from early progression
and those with later progression.
This observation might indicate an association of nu-
cleosome release, tumor growth and treatment effect: high
concentrations of nucleosomes during therapy could be
explained by aggressive tumors with high proliferation
and cell death rates. During the time between the applica-
tions of radiochemotherapy, new subpopulations of un-
differentiated and fragile tumor cells might surge [40],
leading to high cell death rates during the following appli-
cations and to high nucleosome levels in the serum.
Although these tumors might show initial responses to the
treatment, they are at high risk to recur and progress soon.
Thus, high nucleosome concentrations at the initial phase
of therapy might be linked to tumors with high aggressive-
ness and an inefficient long-term response to therapy.
In conclusion, our results indicate that the AUC1–3 of
nucleosomes could be a valuable marker for the early esti-
mation of the progression-free interval in patients with
pancreatic cancer receiving radiochemotherapy.
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